{"analyses":[{"groupDescription":"Week 30","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.14","statisticalComment":"Significance level = 0.05","statisticalMethod":"t-test, 2 sided"},{"groupDescription":"Year 1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.64","statisticalComment":"Significance level = 0.05","statisticalMethod":"t-test, 2 sided"},{"groupDescription":"Year 2","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.18","statisticalComment":"Significance level = 0.05","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.5","value":"-4.9"},{"groupId":"OG001","spread":"8.2","value":"-1.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Week 30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.4","value":"-3.9"},{"groupId":"OG001","spread":"7.1","value":"-2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.5","value":"1.5"},{"groupId":"OG001","spread":"9.6","value":"5.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Year 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"The SAQ-P is an 18-item questionnaire with an overall score range between 0 and 90 including the following domains: desire, dysfunction, activity, satisfaction, and fatigue. The change in SAQ score is calculated by subtracting the baseline score from the follow-up score. A positive change indicates an improvement in sexual well-being.","dispersionType":"Standard Deviation","groups":[{"description":"Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil once daily for 24 weeks.","id":"OG000","title":"Tadalafil"},{"description":"Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Consenting partners of randomized eligible patients with data at baseline and corresponding time point","reportingStatus":"POSTED","timeFrame":"Baseline, week 30 and years 1 and 2 after the start of treatment","title":"Overall Partner Sexual Satisfaction as Measured by Change From Baseline in the Sexual Adjustment Questionnaire-Partner (SAQ-P) Score","type":"SECONDARY","unitOfMeasure":"change in SAQ score"}